β2-Adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis

Circulation

Volumn 101, Issue 1, 2000, Pages 71-77

  Du, X J ^a   Autelitano, Dominic J ^a   Dilley, Rodney J ^a   Wang, Binghui ^a   Dart, Anthony M ^a   Woodcock, Elizabeth A ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Genetics; Heart failure; Hypertrophy; Pressure; Receptors, adrenergic, beta

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BETA 2 ADRENERGIC RECEPTOR; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA STENOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENE TARGETING; HEART FAILURE; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE FIBROSIS; MALE; NONHUMAN; PLEURA EFFUSION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; TRANSGENIC MOUSE;

EID: 0034602839     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.1.71     Document Type: Article

References (34)

1. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol. 1997;80:26L-40L.
2. Horn EM, Bilezikian JP. Mechanisms of abnormal transmembrane signaling of the β-adrenergic receptor in congestive heart failure. Circulation. 1990;82(suppl I):I-26-I-34.
3. 1 receptor messenger RNA abundance in the failing human heart. J Clin Invest. 1993;92:2737-2745.
4. Ungerer M, Parruti G, Böhm M, Puzicha M, DeBlasi A, Erdmann E, Lohse MJ. Expression of β-arrestines and β-adrenergic receptor kinases in the failing human heart. Circ Res. 1994;74:206-213.
5. Muntz KH, Zhao M, Miller JC. Downregulation of myocardial β-adrenergic receptors: receptor subtype selectivity. Circ Res. 1994;74: 369-375.
6. i during pacing-induced heart failure. Circulation. 1996;94:102-107.
7. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with β-adrenergic blockade. J Am Coll Cardiol. 1995;25:1154-1161.
8. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989;79: 483-490.
9. Liang CS, Frantz RP, Suematsu M, Sakamoto S, Sullebarger JT, Fan TM, Guthinger L. Chronic β-adrenoceptor blockade prevents the development of β-adrenergic subsensitivity in experimental right-sided congestive heart failure in dogs. Circulation. 1991;84:254-266.
10. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. Circ Res. 1996;94:2285-2296.
11. Akhter SA, Skaer CA, Kypson AP, McDonald PH, Peppel KC, Glower DD, Lefkowitz RJ, Koch WJ. Restoration of β-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. Proc Natl Acad Sci U S A. 1997;94:12100-12105.
12. Iaccarino G, Tomhave ED, Lefkowitz RJ, Koch WJ. Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by β-adrenergic receptor stimulation and blockade. Circulation. 1998;98: 1783-1789.
13. Koch WJ, Rockman HA, Samama P, Hamilton R, Bond RA, Milano CA, Lefkowitz RJ. Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a βARK inhibitor. Science. 1995;268:1350-1353.
14. 2-adrenergic receptor. Science. 1994; 264:582-586.
15. 2-adrenoceptor. Nature. 1995;374:272-276.
16. Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ, Ross J Jr, Chien KR. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci U S A. 1991;88: 8277-8281.
17. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest. 1994;93:2578-2583.
18. 1-adrenergic receptor subtype mRNAs. J Mol Cell Cardiol. 1998;30:1515-1523.
19. Iwaki K, Sukhatme VP, Shubeita HE, Chien KR. α-and β-adrenergic stimulation induces distinct patterns of immediate early gene expression in neonatal rat myocardial cells. J Biol Chem. 1990;265:13809-13817.
20. Bogoyevitch MA, Andersson MB, Gillespie-Brown J, Clerk A, Glennon PE, Fuller SJ, Sugden PH. Adrenergic receptor stimulation of the mitogen-activated protein kinase cascade and cardiac hypertrophy. Biochem J. 1996;314:115-121.
21. Bishopric NH, Sato B, Webster KA. β-Adrenergic regulation of a myocardial actin gene via a cyclic AMP-independent pathway. J Biol Chem. 1992;267:20932-20936.
22. Iaccarino G, Dolber PC, Lefkowitz RJ, Koch WJ. β-Adrenergic receptor kinase-1 levels in catecholamine-induced myocardial hypertrophy. Circ Res. 1999;33:396-401.
23. Masson S, Arosio B, Luvara G, Gagliano N, Fiordaliso F, Santambrogio D, Vergani C, Latini R, Annoni G. Remodeling of cardiac extracellular matrix during β-adrenergic stimulation: upregulation of SPARC in the myocardium of adult rats. J Mol Cell Cardiol. 1998;30:1505-1514.
24. Benjamin IJ, Jalil JE, Tan LB, Cho K, Weber KT, Clark WA. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res. 1989;65:657-670.
25. Rosenbaum JS, Ginsburg R, Billingham ME, Hoffman BB. Effects of adrenergic receptor antagonists on cardiac morphological and functional alterations in rats harboring pheochromocytoma. J Pharmacol Exp Ther. 1987;241:354-360.
26. sα overexpression. Circ Res. 1996;78:517-524.
27. Arber S, Hunter JJ, Ross J Jr, Hongo M, Sansig G, Borg J, Perriard JC, Chien KR, Caroni P. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy and heart failure. Cell. 1997;88:393-403.
28. Rockman HA, Chien KR, Choi DJ, Iaccarino G, Hunter JJ, Ross J Jr, Lefkowitz RJ, Koch WJ. Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A. 1998;95:7000-7005.
29. Roubin GS, Choong CYP, Devenish-Meares S, Sadick NN, Flelcher PJ, Kelly DT, Harris PJ. β-Adrenergic stimulation of the failing ventricle: a double-blind, randomized trial of sustained oral therapy with prenalterol. Circulation. 1984;69:955-962.
30. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL, the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325:1468-1475.
31. Rockman HA, Choi D, Akhter SA, Jaber M, Giros B, Lefkowitz RJ, Caron MG, Koch WJ. Control of myocardial contractile function by the level of β-adrenergic receptor kinase 1 in gene-targeted mice. J Biol Chem. 1998;273:18180-18184.
32. i proteins and its physiological relevance in murine cardiac myocytes. Circ Res. 1999;84:43-52.
33. Izumo S, Lompre AM, Matsuoka R, Koren G, Schwartz K, Nadal-Ginard B, Mahdavi V. Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. J Clin Invest. 1987;79:970-977.
34. Lowes BD, Minobe W, Abraham WT, Rizeq MN, Bohlmeyer TJ, Quaife RA, Roden RL, Dutcher DL, Robertson AD, Voelkel NF, Badesch DB, Groves BM, Gilbert EM, Bristow MR. Changes in gene expression in the intact human heart: downregulation of α-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest. 1997;100: 2315-2324.